Microscopic Polyangiitis

Lucy Smyth; Gillian Gaskin; Charles D. Pusey

doi:10.1055/s-2004-836144

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2004; 25(5): 523-533
DOI: 10.1055/s-2004-836144

Microscopic Polyangiitis

Lucy Smyth¹ , Gillian Gaskin¹ , Charles D. Pusey¹

¹Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom

Abstract

Microscopic polyangiitis is a systemic vasculitis affecting smal-l and medium-sized vessels and is characteristically associated with a focal and segmental necrotizing glomerulonephritis. It may present as a pulmonary-renal syndrome with rapidly progressive glomerulonephritis and alveolar hemorrhage, but the pattern of disease will vary according to the organ systems involved. Granulomatous disease of the upper or lower respiratory tract is not a feature, and its presence suggests the diagnosis of Wegener's granulomatosis. The etiology of the condition is unclear, but most patients have antineutrophil cytoplasm antibodies (ANCA) with specificity for either myeloperoxidase (MPO) or proteinase 3 (PR3), and there is increasing evidence that these may be pathogenic. Current treatment includes an induction phase using cyclophosphamide and steroids to attain remission, followed by a maintenance phase in which the levels of immunosuppression are gradually reduced. Azathioprine may be substituted for cyclophosphamide at 3 months. Adjunctive plasma exchange or intravenous methylprednisolone is used in the management of either or both severe renal disease and alveolar hemorrhage, and new evidence suggests that plasma exchange is more effective in recovery of renal function. Overall, 1-year survival in systemic vasculitis is around 85%, and up to 50% of patients relapse, although relapse is less common in those with MPO-ANCA. Newer therapies are being explored in an attempt to increase the efficacy and reduce the toxicity of treatment.

KEYWORDS

Systemic vasculitis - ANCA - microscopic polyangiitis

Full Text

References

REFERENCES

1 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994; 37 187-192
2 Davson J, Ball J, Plat R. The kidney in periarteritis nodosa. Q J Med. 1948; 67 175-202
3 Davies D J, Moran J E, Niall J F, Ryan G B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. Br Med J (Clin Res Ed). 1982; 285 606
4 van der Woude F J, Rasmussen N, Lobatto S et al.. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985; 1 425-429
5 Savage C O, Winearls C G, Evans D J, Rees A J, Lockwood C M. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985; 56 467-483
6 Falk R J, Jennette J C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988; 318 1651-1657
7 Goldschmeding R, Dolman K M, van den Ende M E, van der Meer-Gerritsen C H, Sonnenberg A, dem Borne A E. The relation of 29 kD C-ANCA antigen to proteinase 3. APMIS Suppl. 1990; 19 26-27
8 Niles J, McCluskey R, Ahmad M, Arnaout M A. Wegener's granulomatosis autoantigen is a novel serine proteinase. Blood. 1989; 74 1888-1893
9 Tervaert J W, Goldschmeding R, Elema J D et al.. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum. 1990; 33 1264-1272
10 Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med. 1998; 244 209-216
11 Falk R J, Nachman P H, Hogan S L, Jennette J C. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol. 2000; 20 233-243
12 Watts R A, Lane S E, Bentham G, Scott D G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000; 43 414-419
13 Gonzalez-Gay M A, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003; 49 388-393
14 Hogan S L, Satterly K K, Dooley M A, Nachman P H, Jennette J C, Falk R J. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol. 2001; 12 134-142
15 Lane S E, Watts R A, Bentham G, Innes N J, Scott D G. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 2003; 48 814-823
16 Dolman K M, Gans R O, Vervaat T J et al.. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 1993; 342 651-652
17 Kallenberg C G, Rarok A, Stegeman C A, Limburg P C. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. Autoimmun Rev. 2002; 1 61-66
18 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002; 110 955-963
19 Smyth C L, Smith J, Cook H T, Haskard D O, Pusey C D. Anti-myeloperoxidase associated pauci-immune focal segmental glomerulonephritis in rats. Cleve Clin J Med. 2002; 69(suppl 2) 156
20 Guillevin L, Durand-Gasselin B, Cevallos R et al.. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999; 42 421-430
21 Hauer H A, Bajema I M, van Houwelingen H C et al.. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002; 61 80-89
22 Booth A D, Almond M K, Burns A et al.. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003; 41 776-784
23 Franssen C F, Gans R O, Arends B et al.. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int. 1995; 47 193-199
24 Franssen C F, Stegeman C A, Oost-Kort W W et al.. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol. 1998; 9 1915-1923
25 Hogan S L, Nachman P H, Wilkman A S, Jennette J C, Falk R J. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996; 7 23-32
26 Mistry N E, Pusey C D, Gaskin G. Markers of pulmonary haemorrhage in microscopic polyangiitis [abstract]. Sarcoidosis Vasc Diffuse Lung Dis. 1996; 13 268
27 Eschun G M, Mink S N, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest. 2003; 123 297-301
28 Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004; 9 190-196
29 Savige J, Gillis D, Benson E et al.. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999; 111 507-513
30 Fauci A S, Haynes B F, Katz P, Wolff S M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98 76-85
31 Jayne D, Rasmussen N, Andrassy K et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349 36-44
32 Cole E, Cattran D, Magil A et al.. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992; 20 261-269
33 Pusey C D, Rees A J, Evans D J, Peters D K, Lockwood C M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991; 40 757-763
34 Frasca G M, Soverini M L, Falaschini A, Tampieri E, Vangelista A, Stefoni S. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther-Apher Dial. 2003; 7 540-546
35 Bolton W K, Sturgill B C. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol. 1989; 9 368-375
36 Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol. 1991; 35 139-147
37 Gaskin G, Pusey C D. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher. 2001; 5 176-181
38 Gaskin G, Pusey C. Long-term outcome after immunosuppression and plasma exchange for severe vasculitis-associated glomerulonephritis [abstract]. J Am Soc Nephrol. 1999; 10 101A
39 Klemmer P J, Chalermskulrat W, Reif M S, Hogan S L, Henke D C, Falk R J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003; 42 1149-1153
40 de Groot K, Adu D, Savage C O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001; 16 2018-2027
41 Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude F J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999; 10 1965-1971
42 Jayne D R, Chapel H, Adu D et al.. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000; 93 433-439
43 Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross W L. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995; 101 2-7
44 Langford C A, Talar-Williams C, Barron K S, Sneller M C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003; 114 463-469
45 de Groot K, Rasmussen N, Cohen Tervaert J W, Jayne D. Randomised trial of cycophosphamide versus methotrexate for induction of remission in “non-renal” ANCA-associated vasculitis [abstract]. J Am Soc Nephrol. 2002; 13 2A
46 Schmitt W H, Hagen E C, Neumann I, Nowack R, Flores-Suarez L F, van der Woude F J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004; 65 1440-1448
47 Lockwood C M. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond. 1998; 32 473-478
48 Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001; 44 2836-2840
49 Stone J H. Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis. Kidney Blood Press Res. 2003; 26 240-248
50 Booth A, Harper L, Hammad T et al.. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004; 15 717-721
51 Birck R, Warnatz K, Lorenz H M et al.. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol. 2003; 14 440-447
52 Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 1998; 9 1258-1263
53 Stegeman C A, Tervaert J W, van Son W J, Tegzess A M. Necrotizing glomerulonephritis associated with antimyeloperoxidase antibodies in a renal transplant recipient with renal failure of unknown origin. Nephrol Dial Transplant. 1994; 9 839-842
54 Elmedhem A, Adu D, Savage C O. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant. 2003; 18 1001-1004
55 Nachman P H, Segelmark M, Westman K et al.. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int. 1999; 56 1544-1550
56 Gallagher H, Kwan J T, Jayne D R. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis. 2002; 39 42-47
57 Hoffman G S, Kerr G S, Leavitt R Y et al.. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116 488-498
58 Stillwell T J, Benson Jr R C, DeRemee R A, McDonald T J, Weiland L H. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum. 1988; 31 465-470
59 Kamesh L, Harper L, Savage C O. ANCA-positive vasculitis. J Am Soc Nephrol. 2002; 13 1953-1960
60 Bajema I M, Hagen E C, Hermans J et al.. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999; 56 1751-1758
61 Hauer H A, Bajema I M, van Houwelingen H C et al.. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002; 62 1732-1742
62 Jayne D, Rasmussen N, Andrassy K et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349 36-44
63 Nachman P H, Hogan S L, Jennette J C, Falk R J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996; 7 33-39
64 Gaskin G, Savage C O, Ryan J J et al.. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant. 1991; 6 689-694
65 Tervaert J W, Huitema M G, Hene R J et al.. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990; 336 709-711
66 Han W K, Choi H K, Roth R M, McCluskey R T, Niles J L. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int. 2003; 63 1079-1085

Charles D PuseyF.R.C.P.

Renal Section, Division of Medicine, Imperial College London

Hammersmith Hospital, Du Cane Rd.

London W12 0NN, UK

Email: c.pusey@imperial.ac.uk